Degarelix – Uses, Dosage, Side Effects, Interaction

Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Degarelix - Uses, Dosage, Side Effects, Interaction
Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

Degarelix is a parenterally administered, gonadotropin-releasing hormone (GnRH) antagonist that effectively blocks androgen production and is used to treat advanced prostate cancer. Degarelix therapy is associated with serum enzyme elevations during therapy but has yet to be linked to instances of clinically apparent acute liver injury. Testosterone is...

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

Degarelix is a parenterally administered, gonadotropin-releasing hormone (GnRH) antagonist that effectively blocks androgen production and is used to treat advanced prostate cancer. Degarelix therapy is associated with serum enzyme elevations during therapy but has yet to be linked to instances of clinically apparent acute liver injury. Testosterone is a male hormone that promotes the growth of many prostate tumors and therefore reducing circulating testosterone to very low (castration) levels is often...

Key Takeaways

  • This article explains Mechanism of Action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindications in simple medical language.
  • This article explains Dosage in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.
Choose your reading view

Patient View highlights a simple learning journey. Clinical View reveals structure, evidence, and editorial completeness.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
  • New weakness, severe pain, high fever, or symptoms after a serious injury.
  • Any symptom that feels urgent, unusual, or unsafe for the patient.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.

Degarelix Acetate is the acetate form of a long-acting, synthetic peptide with gonadotrophin-releasing hormone (GnRH) antagonistic properties. Degarelix targets and blocks GnRH receptors located on the surfaces of gonadotroph cells in the anterior pituitary, thereby reducing the secretion of luteinizing hormone (LH) by pituitary gonadotroph cells and so decreasing testosterone production by interstitial (Leydig) cells in the testes.

Mechanism of Action

Degarelix competitively inhibits GnRH receptors in the pituitary gland, preventing the release of luteinizing hormone (LH) and follicle-stimulating hormone. Reduced LH suppresses testosterone release, which slows growth and reduces the size of prostate cancers.

Degarelix is a selective gonadotrophin-releasing-hormone (GnRH) antagonist that competitively and reversibly binds to the pituitary GnRH receptors, thereby rapidly reducing the release of the gonadotrophins, luteinizing hormone (LH) and follicle stimulating hormone (FSH), and thereby reducing the secretion of testosterone (T) by the testes. Prostatic carcinoma is known to be androgen-sensitive and responds to treatment that removes the source of androgen. Unlike GnRH agonists, GnRH antagonists do not induce an LH surge with subsequent testosterone surge/tumor stimulation and potential symptomatic flare after the initiation of treatment

or

Degarelix, a synthetic decapeptide, is a gonadotropin-releasing hormone (GnRH, luteinizing hormone-releasing hormone, gonadorelin) antagonist. The drug immediately, competitively, and reversibly binds to and blocks GnRH receptors in the pituitary, thereby reducing the release of gonadotropins (i.e., luteinizing hormone [LH], follicle-stimulating hormone [FSH]) and, consequently, testosterone without initial stimulation of the hypothalamic-pituitary-gonadal axis and the associated testosterone surge. Degarelix appears to have low histamine-releasing potential compared with other GnRH antagonists; there have been no signs of immediate- or late-onset systemic allergic reactions with degarelix. Degarelix is a synthetic derivative of GnRH decapeptide, the ligand of the GnRH receptor. Gonadotropin and androgen production result from the binding of endogenous GnRH to the GnRH receptor. Degarelix antagonizes the GnRH receptor which in turn blocks the release of LH and FSH from the pituitary. LF and FSH decrease in a concentration-dependent manner. The reduction in LH leads to a decrease in testosterone release from the testes.

Gonadotrophin-releasing hormone receptors, GnRH1 and GnRH2 receptors (provisional nomenclature, also called Type I and Type II GnRH receptor, respectively ) have been cloned from numerous species, most of which express two or three types of GnRH receptor. GnRH I (p-Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) is a hypothalamic decapeptide also known as luteinizing hormone-releasing hormone, gonadoliberin, luliberin, gonadorelin or simply as GnRH. It is a member of a family of similar peptides found in many species including GnRH II (pGlu-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH2 (which is also known as chicken GnRH-II). Receptors for three forms of GnRH exist in some species but only GnRH I and GnRH II and their cognate receptors have been found in mammals. GnRH1 receptors are expressed by pituitary gonadotrophs, where they mediate the effects of GnRH on gonadotropin hormone synthesis and secretion that underpin central control of mammalian reproduction. GnRH analogs are used in assisted reproduction and to treat steroid hormone-dependent conditions. Notably, agonists cause desensitization of GnRH-stimulated gonadotropin secretion, and the consequent reduction in circulating sex steroids is exploited to treat hormone-dependent cancers of the breast, ovary, and prostate. GnRH1 receptors are selectively activated by GnRH I and all lack the COOH-terminal tails found in other GPCRs. GnRH2 receptors do have COOH-terminal tails and (where tested) are selective for GnRH II over GnRH I. GnRH2 receptors are expressed by some primates but not by humans. Phylogenetic classifications divide GnRH receptors into three or five groups and highlight examples of gene loss through evolution, with humans retaining only one ancient gene. The structure of the GnRH1 receptor in complex with elagolix has been elucidated.

Indications

  • Degarelix is used for the management of advanced prostate cancer.
  • FIRMAGON is a gonadotrophin-releasing hormone (GnRH) antagonist indicated for the treatment of adult male patients with advanced hormone-dependent prostate cancer for treatment of high-risk localized and locally advanced hormone-dependent prostate cancer in combination with radiotherapy as a neo-adjuvant treatment prior to radiotherapy in patients with high-risk localized or locally advanced hormone dependent prostate cancer.
  • Degarelix is a parenterally administered, gonadotropin-releasing hormone (GnRH) antagonist that effectively blocks androgen production and is used to treat advanced prostate cancer.
  • Intended to treat patients with advanced prostate cancer … slows the growth and progression of prostate cancer by suppressing testosterone

Use in Cancer

Degarelix is approved to treat:

Contraindications

  • low amount of magnesium in the blood
  • low amount of potassium in the blood
  • prolonged QT interval on EKG
  • chronic heart failure
  • abnormal EKG with QT changes from birth
  • liver problems
  • decreased calcification or density of bone
  • pregnancy

Dosage

Strengths: 80 mg; 120 mg

Prostate Cancer

  • Initial Dose: 240 mg administered as 2 subcutaneous injections of 120 mg each at a concentration of 40 mg/mL.
  • Maintenance Dose: 80 mg administered as 1 subcutaneous injection at a concentration of 20 mg/mL every 28 days.
  • Administer the first maintenance dose 28 days after the initial dose.

Renal Dose Adjustments

  • Mild Renal Impairment (CrCl 50 to 80 mL/min): No adjustment recommended.
  • Moderate to Severe Renal Impairment (CrCl less than 50 mL/min): Use with caution.

Liver Dose Adjustments

  • Mild to Moderate Hepatic Impairment (Child-Pugh A and B): No adjustment recommended.
  • Severe Hepatic Impairment (Child-Pugh C): Data not available; use with caution.

Administration Advice:

  • Administer this drug in the abdominal region only.
  • Vary the injection site periodically to minimize patient discomfort, and administer in abdomen areas not exposed to pressure (e.g., not close to the waistband or belt, not close to the ribs).
  • Perform a slow, deep subcutaneous injection over 30 seconds.
  • This drug is for subcutaneous injection only; do not administer intravenously or intramuscularly.
  • Use this drug only as a first-line androgen deprivation therapy; there is no data available on the use of this drug in patients who have failed treatment with GnRH agonists (e.g., leuprorelin, goserelin).
  • Confirm serum testosterone levels are remaining sufficiently suppressed if a patient’s clinical response appears to be sub-optimal.

Side Effects

The Most Common

  • pain, redness, swelling, hardness, or itching in the place where the medication was injected
  • hot flashes
  • excessive sweating or night sweats
  • nausea
  • constipation
  • diarrhea
  • weight gain or loss
  • weakness
  • dizziness
  • pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।" data-rx-term="headache" data-rx-definition="Headache means pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।">headache
  • tiredness
  • difficulty falling asleep or staying asleep
  • enlargement of the breasts
  • decreased sexual desire or ability
  • back or joint pain
  • hives
  • rash
  • difficulty breathing or swallowing
  • rapid, irregular, or pounding heartbeat
  • swelling of the face, throat, tongue, lips, eyes, hands, feet, ankles, or lower legs
  • hoarseness
  • fluttering feeling in the chest
  • fainting
  • painful, frequent, or difficult urination
  • fever or chills

More common

  • pain: Back pain means pain in the spine, muscles, discs, joints, or nerves of the back. সহজ বাংলা: পিঠ/কোমরের ব্যথা।" data-rx-term="back pain" data-rx-definition="Back pain means pain in the spine, muscles, discs, joints, or nerves of the back. সহজ বাংলা: পিঠ/কোমরের ব্যথা।">Back pain
  • blurred vision
  • dizziness
  • fever
  • flushing or redness of the skin
  • hard lump
  • pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।" data-rx-term="headache" data-rx-definition="Headache means pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।">headache
  • nervousness
  • pain
  • pounding in the ears
  • slow or fast heartbeat
  • small lumps under the skin
  • swelling
  • unusually warm skin
  • fast or pounding heartbeats, fluttering in your chest;
  • shortness of breath;
  • sudden dizziness (like you might pass out); or
  • severe pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।" data-rx-term="headache" data-rx-definition="Headache means pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।">headache, blurred vision, and pounding in your neck or ears.
  • hot flashes;
  • abnormal liver function tests; or
  • pain, swelling, redness, itching, or a hard lump where the medicine was injected.
  • weight gain;

Rare

  • Bladder pain
  • bloody or cloudy urine
  • chills
  • decrease in testicle size
  • decreased interest in sexual intercourse
  • difficult, burning, or painful urination
  • difficulty in moving
  • frequent urge to urinate
  • inability to have or keep an erection
  • increased sweating
  • loss in sexual ability, desire, drive, or performance
  • lower back or side pain
  • muscle pain or stiffness
  • pain in the joints
  • Chest pain or discomfort
  • fainting
  • irregular heartbeat
  • pounding heartbeat
  • Cough
  • difficulty swallowing
  • hives, itching, or skin rash
  • puffiness or swelling of the eyelids or around the eyes, face, lips or tongue
  • tightness in the chest
  • trouble breathing
  • unusual tiredness or weakness

Drug Interaction

Pregnancy and Lactation

FDA Pregnancy Risk Category: X 

AU TGA pregnancy category D

Pregnancy

There are no controlled data on human pregnancy. Drugs that have caused, are suspected to have caused, or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in the use of the drug in pregnant women clearly outweigh the potential benefits.

Lactation

There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.

How should this medicine be used?

Degarelix injection comes as a powder to be mixed with liquid and injected under the skin in the stomach area, away from the ribs and waistline. It is usually injected once every 28 days by a doctor or nurse in a medical facility.

After you receive a dose of degarelix injection, be sure that your belt or waistband does not put pressure on the place where the medication was injected.

Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.

Other uses for this medicine

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

What special precautions should I follow?

Before receiving degarelix injection,

  • tell your doctor and pharmacist if you are allergic to degarelix injection, any other medications, or any of the ingredients in degarelix injection. Ask your pharmacist or check the patient’s information for a list of the ingredients.
  • tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: amiodarone (Cordarone), disopyramide (Norpace), quinidine, procainamide, or sotalol (Betapace). Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
  • tell your doctor if you have or have ever had long QT syndrome (a rare heart problem that may cause irregular heartbeat, fainting, or sudden death); high or low levels of calcium, potassium, magnesium, or sodium in your blood; or heart, liver, or kidney disease.
  • women who are or who may become pregnant should not receive degarelix injections. Degarelix injection may harm the fetus. If you receive degarelix injection while you are pregnant, call your doctor immediately. If you are breastfeeding, talk to your doctor before you receive degarelix injection.

References

  1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022201lbl.pdf
  2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022201s011lbl.pdf
  3. https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022201.pdf
  4. https://www.cancer.gov/about-cancer/treatment/drugs/degarelix
  5. https://pubchem.ncbi.nlm.nih.gov/compound/Degarelix
  6. https://pubchem.ncbi.nlm.nih.gov/compound/Degarelix-acetate-hydrate
  7. https://www.drugs.com/degarelix.html
  8. https://go.drugbank.com/drugs/DB06699
  9. https://en.wikipedia.org/wiki/Degarelix
  10. https://medlineplus.gov/druginfo/meds/a609022.html
  11. https://www.webmd.com/drugs/2/drug-151919/degarelix-subcutaneous/details/list-contraindications
  12. https://www.mayoclinic.org/drugs-supplements/degarelix-subcutaneous-route/side-effects/drg-20072529?
  13. NCI Thesaurus Tree
  14. ChemIDplus Chemical Information Classification
  15. CompTox Chemicals Dashboard Chemical Lists
  16. Guide to Pharmacology Target Classification
  17. PubChem
  18. Anatomical Therapeutic Chemical (ATC) classification
    Target-based classification of drugs
  19. NORMAN Suspect List Exchange Classification
  20. NCBI

RX Clinical Pathway Engine

Continue through a complete learning pathway

Move from understanding the topic to symptoms, tests, treatment, medicines, monitoring, and prevention.

Search the complete library
  1. Understand the condition Begin with the essential facts and a clear explanation of the topic.
  2. Recognize symptoms Learn common symptoms, signs, and patterns of presentation.
  3. Know when to seek help Review urgent warning signs and when professional assessment may be needed.
  4. Understand causes and risks Explore causes, risk factors, mechanisms, and contributing conditions.
  5. Explore tests and diagnosis Learn how clinicians assess the condition and which investigations may be discussed.
  6. Learn treatment approaches Review general treatment categories and management principles.
  7. Understand medicines safely Continue to medicine education, uses, precautions, and monitoring.
  8. Plan monitoring and follow-up Understand monitoring, complications, rehabilitation, and follow-up learning.
  9. Review prevention and self-care Explore prevention, healthy routines, and questions to discuss with a clinician.

Conditions & Diseases

Background, symptoms, causes, diagnosis, and care.

Explore this library

Tests & Investigations

Laboratory, imaging, screening, and diagnostic education.

Explore this library

Medicines

Uses, safety, monitoring, and related medicine knowledge.

Explore this library

Cancer Knowledge

Cancer types, screening, oncology, and treatment education.

Explore this library
Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Orthopedic / spine specialist, physical medicine doctor, or qualified clinician
Tests to discuss with doctor
  • Neurological examination for leg power, sensation, reflexes, and straight leg raise
  • X-ray only if injury, deformity, long-lasting pain, or doctor suspects bone problem
  • MRI discussion if severe nerve symptoms, weakness, bladder/bowel problem, or persistent symptoms
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Is physiotherapy, posture correction, or activity modification needed?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Degarelix – Uses, Dosage, Side Effects, Interaction

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Mechanism of Action Degarelix competitively inhibits GnRH receptors in the pituitary gland, preventing the release of luteinizing hormone (LH) and follicle-stimulating hormone. Reduced LH suppresses testosterone release, which slows growth and reduces the size of prostate cancers. Degarelix is a selective gonadotrophin-releasing-hormone (GnRH) antagonist that competitively and reversibly binds to the pituitary GnRH receptors, thereby rapidly reducing the release of the gonadotrophins, luteinizing hormone (LH) and follicle stimulating hormone (FSH), and thereby reducing the secretion of testosterone (T) by the testes. Prostatic carcinoma is known to be androgen-sensitive and responds to treatment that removes the source of androgen. Unlike GnRH agonists, GnRH antagonists do not induce an LH surge with subsequent testosterone surge/tumor stimulation and potential symptomatic flare after the initiation of treatment or Degarelix, a synthetic decapeptide, is a gonadotropin-releasing hormone (GnRH, luteinizing hormone-releasing hormone, gonadorelin) antagonist. The drug immediately, competitively, and reversibly binds to and blocks GnRH receptors in the pituitary, thereby reducing the release of gonadotropins (i.e., luteinizing hormone [LH], follicle-stimulating hormone [FSH]) and, consequently, testosterone without initial stimulation of the hypothalamic-pituitary-gonadal axis and the associated testosterone surge. Degarelix appears to have low histamine-releasing potential compared with other GnRH antagonists; there have been no signs of immediate- or late-onset systemic allergic reactions with degarelix. Degarelix is a synthetic derivative of GnRH decapeptide, the ligand of the GnRH receptor. Gonadotropin and androgen production result from the binding of endogenous GnRH to the GnRH receptor. Degarelix antagonizes the GnRH receptor which in turn blocks the release of LH and FSH from the pituitary. LF and FSH decrease in a concentration-dependent manner. The reduction in LH leads to a decrease in testosterone release from the testes. Gonadotrophin-releasing hormone receptors, GnRH1 and GnRH2 receptors (provisional nomenclature, also called Type I and Type II GnRH receptor, respectively ) have been cloned from numerous species, most of which express two or three types of GnRH receptor. GnRH I (p-Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) is a hypothalamic decapeptide also known as luteinizing hormone-releasing hormone, gonadoliberin, luliberin, gonadorelin or simply as GnRH. It is a member of a family of similar peptides found in many species including GnRH II (pGlu-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH2 (which is also known as chicken GnRH-II). Receptors for three forms of GnRH exist in some species but only GnRH I and GnRH II and their cognate receptors have been found in mammals. GnRH1 receptors are expressed by pituitary gonadotrophs, where they mediate the effects of GnRH on gonadotropin hormone synthesis and secretion that underpin central control of mammalian reproduction. GnRH analogs are used in assisted reproduction and to treat steroid hormone-dependent conditions. Notably, agonists cause desensitization of GnRH-stimulated gonadotropin secretion, and the consequent reduction in circulating sex steroids is exploited to treat hormone-dependent cancers of the breast, ovary, and prostate. GnRH1 receptors are selectively activated by GnRH I and all lack the COOH-terminal tails found in other GPCRs. GnRH2 receptors do have COOH-terminal tails and (where tested) are selective for GnRH II over GnRH I. GnRH2 receptors are expressed by some primates but not by humans. Phylogenetic classifications divide GnRH receptors into three or five groups and highlight examples of gene loss through evolution, with humans retaining only one ancient gene. The structure of the GnRH1 receptor in complex with elagolix has been elucidated. Indications Degarelix is used for the management of advanced prostate cancer. FIRMAGON is a gonadotrophin-releasing hormone (GnRH) antagonist indicated for the treatment of adult male patients with advanced hormone-dependent prostate cancer for treatment of high-risk localized and locally advanced hormone-dependent prostate cancer in combination with radiotherapy as a neo-adjuvant treatment prior to radiotherapy in patients with high-risk localized or locally advanced hormone dependent prostate cancer. Degarelix is a parenterally administered, gonadotropin-releasing hormone (GnRH) antagonist that effectively blocks androgen production and is used to treat advanced prostate cancer. Intended to treat patients with advanced prostate cancer ... slows the growth and progression of prostate cancer by suppressing testosterone Use in Cancer Degarelix is approved to treat: Prostate cancer is advanced. Contraindications low amount of magnesium in the blood low amount of potassium in the blood prolonged QT interval on EKG chronic heart failure abnormal EKG with QT changes from birth liver problems decreased calcification or density of bone pregnancy Dosage Strengths: 80 mg; 120 mg Prostate Cancer Initial Dose: 240 mg administered as 2 subcutaneous injections of 120 mg each at a concentration of 40 mg/mL. Maintenance Dose: 80 mg administered as 1 subcutaneous injection at a concentration of 20 mg/mL every 28 days. Administer the first maintenance dose 28 days after the initial dose. Renal Dose Adjustments Mild Renal Impairment (CrCl 50 to 80 mL/min): No adjustment recommended. Moderate to Severe Renal Impairment (CrCl less than 50 mL/min): Use with caution. Liver Dose Adjustments Mild to Moderate Hepatic Impairment (Child-Pugh A and B): No adjustment recommended. Severe Hepatic Impairment (Child-Pugh C): Data not available; use with caution. Administration Advice: Administer this drug in the abdominal region only. Vary the injection site periodically to minimize patient discomfort, and administer in abdomen areas not exposed to pressure (e.g., not close to the waistband or belt, not close to the ribs). Perform a slow, deep subcutaneous injection over 30 seconds. This drug is for subcutaneous injection only; do not administer intravenously or intramuscularly. Use this drug only as a first-line androgen deprivation therapy; there is no data available on the use of this drug in patients who have failed treatment with GnRH agonists (e.g., leuprorelin, goserelin). Confirm serum testosterone levels are remaining sufficiently suppressed if a patient's clinical response appears to be sub-optimal. Side Effects The Most Common pain, redness, swelling, hardness, or itching in the place where the medication was injected hot flashes excessive sweating or night sweats nausea constipation diarrhea weight gain or loss weakness dizziness headache tiredness difficulty falling asleep or staying asleep enlargement of the breasts decreased sexual desire or ability back or joint pain hives rash difficulty breathing or swallowing rapid, irregular, or pounding heartbeat swelling of the face, throat, tongue, lips, eyes, hands, feet, ankles, or lower legs hoarseness fluttering feeling in the chest fainting painful, frequent, or difficult urination fever or chills More common Back pain blurred vision dizziness fever flushing or redness of the skin hard lump headache nervousness pain pounding in the ears slow or fast heartbeat small lumps under the skin swelling unusually warm skin fast or pounding heartbeats, fluttering in your chest; shortness of breath; sudden dizziness (like you might pass out); or severe headache, blurred vision, and pounding in your neck or ears. hot flashes; abnormal liver function tests; or pain, swelling, redness, itching, or a hard lump where the medicine was injected. weight gain; Rare Bladder pain bloody or cloudy urine chills decrease in testicle size decreased interest in sexual intercourse difficult, burning, or painful urination difficulty in moving frequent urge to urinate inability to have or keep an erection increased sweating loss in sexual ability, desire, drive, or performance lower back or side pain muscle pain or stiffness pain in the joints Chest pain or discomfort fainting irregular heartbeat pounding heartbeat Cough difficulty swallowing hives, itching, or skin rash puffiness or swelling of the eyelids or around the eyes, face, lips or tongue tightness in the chest trouble breathing unusual tiredness or weakness Drug Interaction Acrivastine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Acrivastine. Adenosine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Adenosine. Ajmaline The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Degarelix. Alfuzosin The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Degarelix. Alimemazine The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Degarelix. Amantadine The risk or severity of QTc prolongation can be increased when Amantadine is combined with Degarelix. Amifampridine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Amifampridine. Amiodarone The risk or severity of QTc prolongation can be increased when Degarelix is combined with Amiodarone. Amisulpride The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Degarelix. Amitriptyline The risk or severity of QTc prolongation can be increased when Degarelix is combined with Amitriptyline. Amodiaquine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Degarelix. Amoxapine The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Degarelix. Anagrelide The risk or severity of QTc prolongation can be increased when Degarelix is combined with Anagrelide. Antazoline The risk or severity of QTc prolongation can be increased when Degarelix is combined with Antazoline. Apomorphine The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Degarelix. Arformoterol The risk or severity of QTc prolongation can be increased when Arformoterol is combined with Degarelix. Aripiprazole The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Degarelix. Aripiprazole lauroxil The risk or severity of QTc prolongation can be increased when Degarelix is combined with Aripiprazole lauroxil. Arsenic trioxide The risk or severity of QTc prolongation can be increased when Degarelix is combined with Arsenic trioxide. Artemether The risk or severity of QTc prolongation can be increased when Degarelix is combined with Artemether. Articaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Articaine. Asenapine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Asenapine. Astemizole The risk or severity of QTc prolongation can be increased when Degarelix is combined with Astemizole. Atazanavir The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Degarelix. Atomoxetine The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Degarelix. Atropine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Atropine. Azatadine The risk or severity of QTc prolongation can be increased when Azatadine is combined with Degarelix. Azithromycin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Azithromycin. Bedaquiline The risk or severity of QTc prolongation can be increased when Degarelix is combined with Bedaquiline. Benzatropine The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Degarelix. Benzocaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Benzyl alcohol. Bepridil The risk or severity of QTc prolongation can be increased when Degarelix is combined with Bepridil. Berotralstat The risk or severity of QTc prolongation can be increased when Degarelix is combined with Berotralstat. Bilastine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Bilastine. Bortezomib The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Degarelix. Bretylium The risk or severity of QTc prolongation can be increased when Bretylium is combined with Degarelix. Brompheniramine The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Degarelix. Buclizine The risk or severity of QTc prolongation can be increased when Buclizine is combined with Degarelix. Bupivacaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Bupivacaine. Buserelin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Buserelin. Butacaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Butamben. Butriptyline The risk or severity of QTc prolongation can be increased when Degarelix is combined with Butriptyline. Capsaicin The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Capsaicin. Carbinoxamine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Carbinoxamine. Celiprolol The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Degarelix. Ceritinib The risk or severity of QTc prolongation can be increased when Degarelix is combined with Ceritinib. Cetirizine The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Degarelix. Chlorcyclizine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Chlorcyclizine. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Chloroprocaine. Chloroquine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Chloroquine. Chlorpheniramine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Chlorpheniramine. Chlorpromazine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Chlorpromazine. Chlorprothixene The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Degarelix. Cilostazol The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Degarelix. Cinchocaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Cinchocaine. Cinnarizine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Cinnarizine. Cinoxacin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Cinoxacin. Ciprofloxacin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Ciprofloxacin. Cisapride The risk or severity of QTc prolongation can be increased when Degarelix is combined with Cisapride. Citalopram The risk or severity of QTc prolongation can be increased when Degarelix is combined with Citalopram. Clarithromycin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Clarithromycin. Clemastine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Clemastine. Clofazimine The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Degarelix. Clomipramine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Clomipramine. Clozapine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Clozapine. Cocaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Cocaine. Crizotinib The risk or severity of QTc prolongation can be increased when Degarelix is combined with Crizotinib. Cyclizine The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Degarelix. Cyproheptadine The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Degarelix. Dabrafenib The risk or severity of QTc prolongation can be increased when Degarelix is combined with Dabrafenib. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Degarelix. Dasatinib The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Degarelix. Delafloxacin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Delafloxacin. Delamanid Degarelix may increase the QTc-prolonging activities of Delamanid. Desflurane The risk or severity of QTc prolongation can be increased when Desflurane is combined with Degarelix. Desipramine The risk or severity of QTc prolongation can be increased when Desipramine is combined with Degarelix. Desloratadine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Desloratadine. Deutetrabenazine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Deutetrabenazine. Dexbromphenirami The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Degarelix. Dexchlorphenirami The risk or severity of QTc prolongation can be increased when Degarelix is combined with Dexchlorpheniramine maleate. Digitoxin The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Degarelix. Digoxin The risk or severity of QTc prolongation can be increased when Digoxin is combined with Degarelix. Diltiazem The risk or severity of QTc prolongation can be increased when Degarelix is combined with Diltiazem. Dimenhydrinate The risk or severity of QTc prolongation can be increased when Degarelix is combined with Dimenhydrinate. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Diphenhydramine. Disopyramide The risk or severity of QTc prolongation can be increased when Degarelix is combined with Disopyramide. Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Degarelix. Dofetilide The risk or severity of QTc prolongation can be increased when Degarelix is combined with Dofetilide. Dolasetron The risk or severity of QTc prolongation can be increased when Degarelix is combined with Dolasetron. Domperidone The risk or severity of QTc prolongation can be increased when Degarelix is combined with Domperidone. Dosulepin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Dosulepin. Doxepin The risk or severity of QTc prolongation can be increased when Doxepin is combined with Degarelix. Doxylamine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Degarelix. Dronedarone The risk or severity of QTc prolongation can be increased when Degarelix is combined with Dronedarone. Droperidol The risk or severity of QTc prolongation can be increased when Degarelix is combined with Droperidol. Dyclonine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Dyclonine. Ebastine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Ebastine. Efavirenz The risk or severity of QTc prolongation can be increased when Degarelix is combined with Efavirenz. Eliglustat The risk or severity of QTc prolongation can be increased when Degarelix is combined with Eliglustat. Emedastine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Emedastine. Encainide The risk or severity of QTc prolongation can be increased when Encainide is combined with Degarelix. Encorafenib The risk or severity of QTc prolongation can be increased when Degarelix is combined with Encorafenib. Enoxacin The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Degarelix. Entrectinib The risk or severity of QTc prolongation can be increased when Degarelix is combined with Entrectinib. Epinastine The risk or severity of QTc prolongation can be increased when Epinastine is combined with Degarelix. Eribulin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Eribulin. Erlotinib The risk or severity of QTc prolongation can be increased when Degarelix is combined with Erlotinib. Erythromycin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Erythromycin. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Degarelix. Escitalopram The risk or severity of QTc prolongation can be increased when Degarelix is combined with Escitalopram. Esmolol The risk or severity of QTc prolongation can be increased when Esmolol is combined with Degarelix. Ethosuximide The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Degarelix. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Etidocaine. Ezogabine The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Degarelix. Famotidine The risk or severity of QTc prolongation can be increased when Famotidine is combined with Degarelix. Felbamate The risk or severity of QTc prolongation can be increased when Felbamate is combined with Degarelix. Felodipine The risk or severity of QTc prolongation can be increased when Felodipine is combined with Degarelix. Fexinidazole The risk or severity of adverse effects can be increased when Degarelix is combined with Fexinidazole. Flecainide The risk or severity of QTc prolongation can be increased when Degarelix is combined with Flecainide. Fluconazole The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Degarelix. Fluorouracil The risk or severity of QTc prolongation can be increased when Degarelix is combined with Fluorouracil. Fluoxetine The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Degarelix. Flupentixol The risk or severity of QTc prolongation can be increased when Degarelix is combined with Flupentixol. Fluspirilene The risk or severity of QTc prolongation can be increased when Degarelix is combined with Fluspirilene. Formoterol The risk or severity of QTc prolongation can be increased when Formoterol is combined with Degarelix. Foscarnet The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Degarelix. Fostemsavir The risk or severity of QTc prolongation can be increased when Degarelix is combined with Fostemsavir. Gadobenic acid The risk or severity of QTc prolongation can be increased when Degarelix is combined with Gadobenic acid. Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Degarelix. Gatifloxacin The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Degarelix. Gemifloxacin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Gemifloxacin. Gilteritinib The risk or severity of QTc prolongation can be increased when Degarelix is combined with Gilteritinib. Glasdegib The risk or severity of QTc prolongation can be increased when Degarelix is combined with Glasdegib. Goserelin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Goserelin. Granisetron The risk or severity of QTc prolongation can be increased when Degarelix is combined with Granisetron. Grepafloxacin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Grepafloxacin. Halofantrine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Halofantrine. Haloperidol The risk or severity of QTc prolongation can be increased when Degarelix is combined with Haloperidol. Histrelin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Histrelin. Hydrochlorothia The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Degarelix. Hydroxychloroq The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Degarelix. Hydroxyzine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Hydroxyzine. Hyoscyamine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Degarelix. Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Degarelix. Ibutilide The risk or severity of QTc prolongation can be increased when Degarelix is combined with Ibutilide. Iloperidone The risk or severity of QTc prolongation can be increased when Degarelix is combined with Iloperidone. Imatinib The risk or severity of QTc prolongation can be increased when Degarelix is combined with Imatinib. Imipramine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Imipramine. Indacaterol The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Degarelix. Indapamide The risk or severity of QTc prolongation can be increased when Indapamide is combined with Degarelix. Inotersen The risk or severity of QTc prolongation can be increased when Degarelix is combined with Inotersen. Isoflurane The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Degarelix. Isradipine The risk or severity of QTc prolongation can be increased when Isradipine is combined with Degarelix. Itraconazole The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Degarelix. Ivabradine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Ivabradine. Ivosidenib The risk or severity of QTc prolongation can be increased when Degarelix is combined with Ivosidenib. Ketoconazole The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Degarelix. Lacidipine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Lacidipine. Lamotrigine The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Degarelix. Lapatinib The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Degarelix. Lefamulin Lefamulin may increase the QTc-prolonging activities of Degarelix. Lenvatinib The risk or severity of QTc prolongation can be increased when Degarelix is combined with Lenvatinib. Leuprolide The risk or severity of QTc prolongation can be increased when Degarelix is combined with Leuprolide. Levacetylmethadol The risk or severity of QTc prolongation can be increased when Degarelix is combined with Levacetylmethadol. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Levobupivacaine. Levocabastine The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Degarelix. Levocetirizine The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Degarelix. Levofloxacin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Levofloxacin. Levomenthol The risk or severity of QTc prolongation can be increased when Levomenthol is combined with Degarelix. Levosimendan The risk or severity of QTc prolongation can be increased when Degarelix is combined with Levosimendan. Lidocaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Lidocaine. Lidoflazine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Lidoflazine. Lofexidine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Lofexidine. Lomefloxacin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Lomefloxacin. Loperamide The risk or severity of QTc prolongation can be increased when Degarelix is combined with Loperamide. Lopinavir The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Degarelix. Losartan The risk or severity of QTc prolongation can be increased when Losartan is combined with Degarelix. Lumefantrine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Lumefantrine. Lurasidone The risk or severity of QTc prolongation can be increased when Degarelix is combined with Lurasidone. Macimorelin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Macimorelin. Maprotiline The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Degarelix. Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Degarelix. Meloxicam The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Meloxicam. Mepivacaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Mepivacaine. Mepyramine The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Degarelix. Mesoridazine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Mesoridazine. Methadone The risk or severity of QTc prolongation can be increased when Degarelix is combined with Methadone. Methotrimeprazine The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Degarelix. Methoxy The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Degarelix. Methsuximide The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Degarelix. Metoclopramide The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Degarelix. Metronidazole The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Degarelix. Mifepristone The risk or severity of QTc prolongation can be increased when Degarelix is combined with Mifepristone. Mirabegron The risk or severity of QTc prolongation can be increased when Degarelix is combined with Mirabegron. Mirtazapine The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Degarelix. Mizolastine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Mizolastine. Mobocertinib The risk or severity of QTc prolongation can be increased when Degarelix is combined with Mobocertinib. Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Degarelix. Moricizine The risk or severity of QTc prolongation can be increased when Moricizine is combined with Degarelix. Moxifloxacin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Moxifloxacin. Nalidixic acid The risk or severity of QTc prolongation can be increased when Degarelix is combined with Nalidixic acid. Nelfinavir The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Degarelix. Nicardipine The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Degarelix. Nifedipine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Nifedipine. Nilotinib The risk or severity of QTc prolongation can be increased when Degarelix is combined with Nilotinib. Nilvadipine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Nilvadipine. Nimodipine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Nimodipine. Nitrendipine The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Degarelix. Norfloxacin The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Degarelix. Nortriptyline The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Degarelix. Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Degarelix. Ofloxacin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Ofloxacin. Olanzapine The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Degarelix. Olodaterol The risk or severity of QTc prolongation can be increased when Degarelix is combined with Olodaterol. Ondansetron The risk or severity of QTc prolongation can be increased when Degarelix is combined with Ondansetron. Orphenadrine The risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Degarelix. Oxaliplatin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Oxaliplatin. Oxatomide The risk or severity of QTc prolongation can be increased when Degarelix is combined with Oxatomide. Oxetacaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Oxetacaine. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Oxybuprocaine. Oxytocin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Degarelix. Pacritinib The risk or severity of QTc prolongation can be increased when Degarelix is combined with Pacritinib. Paliperidone The risk or severity of QTc prolongation can be increased when Degarelix is combined with Paliperidone. Panobinostat The risk or severity of QTc prolongation can be increased when Degarelix is combined with Panobinostat. Papaverine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Papaverine. Pasireotide The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Degarelix. Pazopanib The risk or severity of QTc prolongation can be increased when Degarelix is combined with Pazopanib. Pefloxacin The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Degarelix. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Degarelix. Pentamidine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Pentamidine. Perflutren The risk or severity of QTc prolongation can be increased when Degarelix is combined with Perflutren. Perhexiline The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Degarelix. Pheniramine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Degarelix. Phenol The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Phenol. Pimozide The risk or severity of QTc prolongation can be increased when Degarelix is combined with Pimozide. Pinaverium The risk or severity of QTc prolongation can be increased when Degarelix is combined with Pinaverium. Pitolisant Degarelix may increase the QTc-prolonging activities of Pitolisant. Ponesimod The risk or severity of bradycardia can be increased when Ponesimod is combined with Degarelix. Posaconazole The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Degarelix. Pramocaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Pramocaine. Pregabalin The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Degarelix. Prenylamine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Prenylamine. Prilocaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Prilocaine. Primaquine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Primaquine. Probucol The risk or severity of QTc prolongation can be increased when Degarelix is combined with Probucol. Procainamide The risk or severity of QTc prolongation can be increased when Degarelix is combined with Procainamide. Procaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Procaine. Prochlorperazine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Prochlorperazine. Promazine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Promazine. Promethazine The risk or severity of QTc prolongation can be increased when Promethazine is combined with Degarelix. Propafenone The risk or severity of QTc prolongation can be increased when Degarelix is combined with Propafenone. Proparacaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Proparacaine. Propofol The risk or severity of QTc prolongation can be increased when Propofol is combined with Degarelix. Propoxycaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Propoxycaine. Protriptyline The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Degarelix. Quetiapine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Quetiapine. Quinidine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Quinidine. Quinine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Quinine. Ranolazine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Ranolazine. Relugolix The risk or severity of QTc prolongation can be increased when Degarelix is combined with Relugolix. Ribociclib The risk or severity of QTc prolongation can be increased when Degarelix is combined with Ribociclib. Rilpivirine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Rilpivirine. Risperidone The risk or severity of QTc prolongation can be increased when Risperidone is combined with Degarelix. Ritonavir The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Degarelix. Romidepsin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Romidepsin. Ropivacaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Ropivacaine. Rosoxacin The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Degarelix. Roxithromycin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Roxithromycin. Rupatadine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Rupatadine. Salbutamol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Degarelix. Salmeterol The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Degarelix. Saquinavir The risk or severity of QTc prolongation can be increased when Degarelix is combined with Saquinavir. Sevoflurane The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Degarelix. Solifenacin The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Degarelix. Sorafenib The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Degarelix. Sotalol The risk or severity of QTc prolongation can be increased when Degarelix is combined with Sotalol. Sparfloxacin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Sparfloxacin. Sulfamethoxazole The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Degarelix. Sulfisoxazole The risk or severity of QTc prolongation can be increased when Degarelix is combined with Sulfisoxazole. Sulpiride The risk or severity of QTc prolongation can be increased when Degarelix is combined with Sulpiride. Sultopride The risk or severity of QTc prolongation can be increased when Degarelix is combined with Sultopride. Sunitinib The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Degarelix. Tacrolimus The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Degarelix. Tamoxifen The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Degarelix. Telavancin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Telavancin. Telithromycin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Telithromycin. Terbutaline The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Degarelix. Terfenadine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Terfenadine. Terlipressin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Terlipressin. Tetrabenazine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Tetrabenazine. Tetracaine The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Tetracaine. Thioridazine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Thioridazine. Thiothixene The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Degarelix. Timolol The risk or severity of QTc prolongation can be increased when Timolol is combined with Degarelix. Tizanidine The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Degarelix. Tolterodine The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Degarelix. Toremifene The risk or severity of QTc prolongation can be increased when Degarelix is combined with Toremifene. Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Degarelix. Treprostinil The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Degarelix. Triclabendazole The risk or severity of QTc prolongation can be increased when Degarelix is combined with Triclabendazole. Trimebutine The risk or severity of QTc prolongation can be increased when Degarelix is combined with Trimebutine. Trimethadione The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Degarelix. Trimipramine The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Degarelix. Triprolidine The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Degarelix. Triptorelin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Triptorelin. Trovafloxacin The risk or severity of QTc prolongation can be increased when Degarelix is combined with Trovafloxacin. Valproic acid The risk or severity of QTc prolongation can be increased when Degarelix is combined with Valproic acid. Vandetanib The risk or severity of QTc prolongation can be increased when Degarelix is combined with Vandetanib. Vardenafil The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Degarelix. Vemurafenib The risk or severity of QTc prolongation can be increased when Degarelix is combined with Vemurafenib. Vernakalant The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Degarelix. Vilanterol The risk or severity of QTc prolongation can be increased when Degarelix is combined with Vilanterol. Voriconazole The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Degarelix. Vorinostat The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Degarelix. Ziprasidone The risk or severity of QTc prolongation can be increased when Degarelix is combined with Ziprasidone. Zonisamide The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Degarelix. Zuclopenthixol The risk or severity of QTc prolongation can be increased when Degarelix is combined with Zuclopenthixol. Pregnancy and Lactation FDA Pregnancy Risk Category: X  AU TGA pregnancy category D Pregnancy There are no controlled data on human pregnancy. Drugs that have caused, are suspected to have caused, or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in the use of the drug in pregnant women clearly outweigh the potential benefits. Lactation There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. How should this medicine be used?

Degarelix injection comes as a powder to be mixed with liquid and injected under the skin in the stomach area, away from the ribs and waistline. It is usually injected once every 28 days by a doctor or nurse in a medical facility. After you receive a dose of degarelix injection, be sure that your belt or waistband does not put pressure on the place where the medication was injected. Ask your pharmacist or doctor for a copy of the…

Continue exploring

Explore this topic across the RX Medical Library

Open a focused A–Z pathway or continue with closely related indexed articles. These links are educational and do not replace personal medical care.

Search this topic
Diseases A–Z Drugs A–Z Lab Tests A–Z Cancer A–Z
Diseases A–Z

Foodborne Illness (also foodborne disease and colloquially referred to as food poisoning)[rx] is any illness resulting from the spoilage of contaminated food, pathogenic bacteria, viruses, or parasites that…